Precision

Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

Retrieved on: 
Wednesday, September 27, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Precision BioSciences, Patent, MELAS, CRISPR, DNA, University, Mitochondrion, Gene editing, RNA, Doctor of Philosophy, Precision, Disorder, Mitochondrial myopathy, Cell biology, Patient, Anatomy, Entrepreneurship, Lactic acidosis, Vaccine, Neurology

18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.” Once issued, the patent arising from this application will have a standard expiration date in April 2042.

Key Points: 
  • 18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.” Once issued, the patent arising from this application will have a standard expiration date in April 2042.
  • The allowed composition of matter claims in this U.S. application encompass a mitochondria-targeted ARCUS nuclease (mitoARCUS) that is designed to specifically target, cleave, and eliminate mutant mitochondrial DNA comprising an m.3243A>G mutation.
  • Precision recently announced PBGENE-PMM, the Company’s clinical candidate targeting mutant mitochondrial DNA, as a potentially first-in-class opportunity for treatment of m.3243 associated primary mitochondrial myopathy.
  • Utilizing the claimed mitoARCUS nuclease, PBGENE-PMM is designed to target and eliminate mutant mitochondrial DNA, allowing for repopulation by wild-type mitochondrial DNA and restoration of mitochondrial function.

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

Retrieved on: 
Tuesday, September 26, 2023
Pancreatic cancer, Drug development, Chief Medical Advisor to the President, Oncolytics Biotech, Progression-free survival, Pancreatic Cancer Action Network, Clinical trial, Therapy, AB, Hope, Fast Track, MBA, Research, FOLFIRINOX, RNA, Progress, Doctor of Philosophy, Precision, Plasma protein binding, Science, ONC, G20 World Brain Mapping & Therapeutic Scientific Summit, Community, Patient, SAN, Vutrisiran, Cancer, TSX, Neoplasm, FDA, Gemcitabine, Safety, Disease, Pharmaceutical industry

BOSTON, SAN DIEGO, and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. (NASDAQ: ONCY) (TSX: ONC) as the recipient of its second annual PanCAN Therapeutic Accelerator Award. Oncolytics received this award in recognition of its promising work on pelareorep, an investigational immunotherapy treatment that introduces double-stranded RNA into cancer cells, which stimulates anticancer inflammatory effects, including innate and adaptive immune responses and the activation and recruitment of T cells into the tumor. This $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics' proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.

Key Points: 
  • If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.
  • Testing pelareorep in combination with FOLFIRINOX expands the approach so all patients with advanced pancreatic cancer could have the opportunity to benefit from this innovative immunotherapeutic approach.
  • Oncolytics was selected to receive the 2023 PanCAN Therapeutic Accelerator Award for $5 million through a rigorous, competitive process involving scientific, business and programmatic review from leading experts in the field.
  • The funding offered through the PanCAN Therapeutic Accelerator Award represents an innovative and groundbreaking way for a non-profit to accelerate drug development.

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

Retrieved on: 
Tuesday, September 26, 2023
Pancreatic cancer, Drug development, Chief Medical Advisor to the President, Oncolytics Biotech, Progression-free survival, Pancreatic Cancer Action Network, Clinical trial, Therapy, AB, Hope, Fast Track, MBA, Research, FOLFIRINOX, RNA, Progress, Doctor of Philosophy, Precision, Plasma protein binding, Science, ONC, G20 World Brain Mapping & Therapeutic Scientific Summit, Community, Patient, SAN, Vutrisiran, Cancer, TSX, Neoplasm, FDA, Gemcitabine, Safety, Disease, Pharmaceutical industry

BOSTON, SAN DIEGO, and CALGARY, AB, Sept. 26, 2023 /PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. (NASDAQ: ONCY) (TSX: ONC) as the recipient of its second annual PanCAN Therapeutic Accelerator Award. Oncolytics received this award in recognition of its promising work on pelareorep, an investigational immunotherapy treatment that introduces double-stranded RNA into cancer cells, which stimulates anticancer inflammatory effects, including innate and adaptive immune responses and the activation and recruitment of T cells into the tumor. This $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics' proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.

Key Points: 
  • If results are encouraging, the treatment combination may be advanced to late-stage clinical development through the PanCAN Precision PromiseSM adaptive clinical trial platform.
  • Testing pelareorep in combination with FOLFIRINOX expands the approach so all patients with advanced pancreatic cancer could have the opportunity to benefit from this innovative immunotherapeutic approach.
  • Oncolytics was selected to receive the 2023 PanCAN Therapeutic Accelerator Award for $5 million through a rigorous, competitive process involving scientific, business and programmatic review from leading experts in the field.
  • The funding offered through the PanCAN Therapeutic Accelerator Award represents an innovative and groundbreaking way for a non-profit to accelerate drug development.

Cartoon Animator Unveils Game-Changing 5.2 Updates: Automated Animation with Cursor-Led Movement

Retrieved on: 
Thursday, September 21, 2023
Trigger, Linearity, Bézier, Education, CTA, Orientation, Precision, Movement, Motion, Animation, SAN, Commerce, XYZ, Character, 3D printing, Electric motor, Road, Telescopic sight

SAN JOSE, Calif., Sept. 21, 2023 /PRNewswire-PRWeb/ -- Cartoon Animator (CTA) has been continuously evolving its features in recent years, offering unprecedented capabilities to enhance 2D animation production. With its latest features, the lines between play and creation continue to blur as creative ideas are brought to the forefront with cutting-edge tools as tangible real-time productions.

Key Points: 
  • SAN JOSE, Calif., Sept. 21, 2023 /PRNewswire-PRWeb/ -- Cartoon Animator (CTA) has been continuously evolving its features in recent years, offering unprecedented capabilities to enhance 2D animation production.
  • The 5.2 update introduces two major highlights: Motion Path Animation and Motion Pilot , the natural evolution of contemporary puppetry.
  • With CTA 5.2, barriers to entry in animation are dismantled, propelling you to the next level in the world of 2D animation.
  • Moreover, Cartoon Animator's intuitive interface and real-time animation, combined with seamless keyframe editing, enable you to generate 2D animations in mere seconds.

Huawei Releases the White Paper on Architecture for Intelligent Transformation of Public Services

Retrieved on: 
Thursday, September 21, 2023
CONNECT, Intelligence, Learning, Human rights and encryption, United States Geospatial Intelligence Foundation, Education, White paper, Bush School of Government and Public Service, Public service, Architecture, Precision, Government, Public sector, HUAWEI, City, Artificial Intelligence Applications Institute, Retail, Huawei

At the event, Huawei released the White Paper on Architecture for Intelligent Transformation of Public Services, and global public services pioneers shed light on intelligent transformation trends and implementation directions, to make public services more inclusive and well-targeted.

Key Points: 
  • At the event, Huawei released the White Paper on Architecture for Intelligent Transformation of Public Services, and global public services pioneers shed light on intelligent transformation trends and implementation directions, to make public services more inclusive and well-targeted.
  • The White Paper on Architecture for Intelligent Transformation of Public Services released.
  • Hong-Eng Koh, Chief Scientist of Huawei Global Public Sector, noted: the Architecture for Intelligent Transformation of Public Services consists of Intelligent Sensing, Intelligent Connectivity, Intelligent Foundation, Intelligent platforms, AI Large Models, and Intelligent Applications.
  • Huawei intelligent transformation of public services focuses on four scenarios:
    Intelligent education: The intelligent transformation brings about education that knows no boundaries and provides proactive and intelligent teaching services, extending school education from a classroom-bound experience to learning at anytime, anywhere.

Precision Drilling Announces Acquisition of CWC Energy Services

Retrieved on: 
Thursday, September 7, 2023
Well, LLP, PD, CWC, Disclosure, AC, Precision, EBITDA, Acquisition, PDS, Hoskin, Precision Drilling, SEDAR, Material, TSX, Toronto Stock Exchange, Competition Bureau, NYSE, News, High performance organization, Security (finance)

Precision Drilling Corporation (“Precision”) (TSX:PD; NYSE:PDS) is pleased to announce that it has entered into an agreement to acquire all of the issued and outstanding common shares of CWC Energy Services Corp. ("CWC") (TSXV:CWC) for total consideration of approximately $141 million, comprised of 947,909 Precision shares, valued at approximately $88 million as of September 1, 2023 market close, $14 million in cash, plus the assumption of CWC’s outstanding debt.

Key Points: 
  • Precision Drilling Corporation (“Precision”) (TSX:PD; NYSE:PDS) is pleased to announce that it has entered into an agreement to acquire all of the issued and outstanding common shares of CWC Energy Services Corp. ("CWC") (TSXV:CWC) for total consideration of approximately $141 million, comprised of 947,909 Precision shares, valued at approximately $88 million as of September 1, 2023 market close, $14 million in cash, plus the assumption of CWC’s outstanding debt.
  • With this transaction, Precision adds to its fleet: 62 marketed service rigs in Canada, seven marketed drilling rigs in Canada, and 11 marketed drilling rigs in the U.S., including seven AC triple rigs.
  • Currently, three of the Canadian drilling rigs and seven of the U.S. drilling rigs are actively working for customers.
  • Evercore is acting as financial advisor and Osler, Hoskin & Harcourt LLP is acting as legal advisor to Precision.

Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

Retrieved on: 
Tuesday, September 12, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Oncology, Hemoglobinopathy, Heart, Precision BioSciences, DNA, University, Chief research officer, Event, Mitochondrion, Medicine, Gene editing, Diaphragm, CTA, PMM, Hepatitis, AAV, Precision, ID, Skeletal muscle, Mitochondrial myopathy, DMD, Novartis, Patient, OTC, Sickle cell disease, Webcast, Neurology, Entrepreneurship, Mitochondrial disease, Therapy, IND, HBV, Genome, Video game, Vaccine, Lilly

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the Company plans to highlight its current development programs, pipeline updates, and underlying ARCUS platform technology during a virtual R&D Day to be held today at 9:00 AM ET.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the Company plans to highlight its current development programs, pipeline updates, and underlying ARCUS platform technology during a virtual R&D Day to be held today at 9:00 AM ET.
  • “At Precision, we are moving forward with a renewed identity and focus on our core foundational strength as a gene editing company.
  • “In addition to illustrating where we see a clear advantage for ARCUS, we will drill down on the novel attributes of ARCUS that inform our development program strategy.
  • “Together with PBGENE-HBV, we believe that both of these programs are emblematic of the unique advantages of our ARCUS technology.

Limaca Medical Receives FDA 510(k) Clearance for its Breakthrough Precision GI™ Endoscopic Biopsy Device

Retrieved on: 
Monday, September 11, 2023
Pancreatic cancer, Rambam Health Care Campus, IGY, Precision, Acquisition, MD, Patient, EUS, Blood, Diagnosis, Neoplasm, FDA, GI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Biopsy, Medical device, Medical imaging

YOKNEAM, Israel, Sept. 11, 2023 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration ("FDA").

Key Points: 
  • YOKNEAM, Israel, Sept. 11, 2023 /PRNewswire/ -- Limaca Medical ("Limaca") announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration ("FDA").
  • This follows Limaca's receipt of FDA Breakthrough Device Designation for its Precision GI™.
  • FDA clearance allows us to bring Precision GI™ to market to fulfill our mission to always achieve precise, efficient, and definitive biopsy samples."
  • Carl Rickenbaugh, Limaca Vice Chair, added, "We are pleased with FDA's clearance of Precision GI™, following our FDA Breakthrough Device Designation.

Richardson Electronics, Ltd. Introduces New Consumables for Fiber Lasers at FABTECH 2023

Retrieved on: 
Wednesday, September 6, 2023
McCormick Place, Fiber laser, Electronics, Precision, Laser, KW, Copper, Classic, CO2, Powder metallurgy, Printed circuit board, Sapphire

This new line includes nozzles for use in Bystronic® Fiber Laser machines with automatic nozzle changer.

Key Points: 
  • This new line includes nozzles for use in Bystronic® Fiber Laser machines with automatic nozzle changer.
  • Among our newest protective windows is the 34 x 3 mm Sapphire protective window used in high-power Bystronic® lasers.
  • Richardson Electronics is your one-stop shop for your fiber and CO2 laser needs.
  • All parts advertised are made for and/or by Richardson Electronics, Ltd. We are not implying in any way that our products are original equipment parts.

Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

Retrieved on: 
Thursday, August 31, 2023
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Precision BioSciences, Webcast, Gene editing, R, ID, Precision, Video game

Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET.
  • Precision’s gene editing event will feature presentations from Company management as well as key opinion leaders.
  • The R&D Day event will reflect Precision’s go-forward singular focus on in vivo gene editing through ARCUS, its proprietary, wholly owned genome editing platform.
  • The agenda will include an overview of the broad potential and differentiation of ARCUS, new pre-clinical data, and timelines for leading in vivo gene editing programs.